Compare JD.Com Inc (JD) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JD.Com Inc vs TransMedics Group Inc — how do they compare? JD.Com Inc trades at $30.29 (market cap $41.80B), while TransMedics Group Inc trades at $73.5 (market cap $2.54B). The key difference: JD.Com Inc is far larger — about 16.5× TransMedics Group Inc's market cap, and JD.Com Inc pays a 3.27% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| JD | TMDX | |
|---|---|---|
Market Cap | $41.80B | $2.54B |
Sector | Consumer Cyclical | Technology |
52-Week High | $36.17 | $150.42 |
52-Week Low | $25.19 | $61.99 |
Enterprise Value | $27.96B | $2.94B |
Dividend Yield | 3.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JD.com trades at $30.43, up 2.73% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q1 2026 EPS of $0.74 exceeding expectations. Revenue reached $1.31 trillion in 2025, though net margins compressed to 1.05%. Technical indicators signal bullish momentum with the stock trading near key resistance levels.
Wall Street maintains strong bullish outlook with 69.6% buy ratings and $39.50 consensus target, representing 30% upside potential. Key risks include margin pressure, regulatory investigations, and Chinese market volatility. The company's aggressive buyback program and AI investments provide fundamental support despite competitive pressures.
TransMedics (TMDX) is trading at $73.47, down 0.69% on the day, amid a mixed technical and fundamental backdrop. The stock shows neutral technical signals with support near $72 and resistance at $75, while fundamentals are strong with a trailing P/E of 16.81 and robust profitability metrics like a 27.04% net income margin. Recent earnings saw a Q1 2026 miss but beats in prior quarters, and the company is expanding in Europe through strategic investments.
The outlook is cautiously optimistic with a consensus price target of $108.71 implying significant upside, supported by 75% analyst buy ratings. Key risks include margin pressure from expansion costs and competitive threats, but the company's organ transplant logistics network offers a durable competitive advantage for long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
